Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Bill Newell, the company's Chief Executive Officer, will deliver a presentation on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA.

The presentation will be available to view through the News & Events page in the Investor Relations section of Sutro's website at www.sutrobio.com. An archived version of the presentation will remain accessible for a minimum of 30 days following the event.

News Market Reaction – STRO

-3.47%

-3.47% Session move

In the trading session that priced this news, STRO declined 3.47%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA. 

The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will be available for at least 30 days after the event. 

About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF^®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

When is Sutro Biopharma (STRO) presenting at the 2025 J.P. Morgan Healthcare Conference?

Sutro Biopharma will present on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA.

How long will Sutro Biopharma's (STRO) J.P. Morgan Healthcare Conference presentation be available online?

The presentation will be archived and available for at least 30 days after the event on Sutro's website.

Where can investors access Sutro Biopharma's (STRO) J.P. Morgan Healthcare Conference presentation?

Investors can access the presentation through the News & Events page of the Investor Relations section on www.sutrobio.com.

What type of therapeutic products does Sutro Biopharma (STRO) develop?

Sutro Biopharma is a clinical-stage oncology company that develops site-specific and novel-format antibody drug conjugates (ADCs).